Meet Phat Le, M.D.
Phat Le, M.D.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Gastrointestinal (GI) Medical Oncology (Joint Appointment), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Oncology Lead (HALs Sugar Land), Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2009 | UT Southwestern Medical School, Dallas, Texas, US, MD |
| 2005 | University of Texas at Austin, Austin, Texas, US, Microbiology, BS |
Postgraduate Training
| 2020-2020 | Epic Certification, Epic Power User, MD Anderson Cancer Center, HOUSTON, Texas |
| 2020-2021 | Leading Others Accelerate Program, Leadership, MD Anderson Cancer Center, HOUSTON, Texas |
| 2020-2020 | Clinical Safety and Effectiveness, Clinical Safety and Effectiveness, MD Anderson Cancer Center, HOUSTON, Texas |
| 2012-2015 | Clinical Fellowship, Hematology/Oncology, UT Southwestern Medical Center, Dallas, Texas |
| 2009-2012 | Clinical Residency, UT Southwestern Medical Center, Dallas, Texas |
Board Certifications
| 2024 | DEA |
| 2012 | American Board of Internal Medicine - Medical Oncology |
Experience & Service
Academic Appointments
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2022
Clinical Assistant Professor, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX, 2017 - 2018
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2022
Assistant Professor, Department of General Oncology, Houston Methodist Institute for Academic Medicine/Weill Cornell Medical College, Houston, TX, 2016 - 2017
Assistant Professor, Houston Methodist Specialty Physicians Group, Houston, TX, 2015 - 2017
Administrative Appointments/Responsibilities
Beacon Oncology User Group Committee Member, Parkland Health and Hospital System, Dallas, TX, 2014 - 2015
Chief Hematology/Oncology Fellow, University of Texas Southwestern, Dallas, TX, 2014 - 2015
Parkland Oncology Clinic Staff Committee Member, Parkland Health and Hospital System, Dallas, TX, 2014 - 2015
Institutional Committee Activities
Member, Histotripsy Oversight Committee, 2024 - Present
Quality Goal SuperUser, OP-35 Service Line Steering Committee, 2024 - Present
Member, Rapid Turn Around Time Liquid Biopsy Working Group, 2023 - Present
Chair, Colorectal Multidisciplinary Working Group, 2022 - 2023
Member, GI Service Line Workgroup Local Provider Referral Committee, 2021 - 2022
Member, Flush Therapy Plan Project Committee, 2021 - 2024
Houston Area Location Integration Work Group Co-Lead, GI Service Line Workgroup, 2021 - Present
Member, GI Medical Oncology Burnout Task Force, 2021 - 2022
Member, Houston Area Locations Research Expansion Operations Committee, 2020 - 2021
Member, Ambulatory Informatics Committee, 2020 - Present
Member, Faculty Senate Houston Area Locations Working Group, 2020 - 2020
Chair, ad interim, HALS Clinical Research Committee, 2019 - 2020
Department Representative, Faculty Senate, 2019 - 2021
Member, EHR Provider Experience Subcommittee, 2018 - 2019
Officer, Department EHR Committee, 2018 - Present
Medical Oncology Representative, HALS Clinical Research Steering Committee, 2017 - 2020
Member, Houston Methodist Cancer Center EPIC Validation Committee, 2015 - 2017
Member, Cancer Committee, 2015 - 2017
Honors & Awards
| 2024 | Zero Heroes-Providers who had 1000+ encounters closed on average in less than 1 day, MD Anderson Cancer Center |
| 2021 - 2022 | Zero Heroes-Providers who had 1000+ encounters closed on average in less than 1 day, MD Anderson Cancer Center |
| 2020 | Top 10% Provider, Clinician and Group Consumer Assessment of Healthcare Providers and Systems |
| 2019 | Top Houston Area Location Provider for Research Referrals, MD Anderson Cancer Center |
| 2019 | You Make the Difference-Fastest to Close Encounters, MD Anderson Cancer Center, Division of Cancer Medicine 14th Annual Faculty Recognition and Awards Program |
| 2019 | Top HALS Provider for Research Referrals, MD Anderson Cancer Center |
| 2018 | Top 1% Provider, Clinician and Group Consumer Assessment of Healthcare Providers and Systems |
| 2014 - 2015 | UT Southwestern Hematology/Oncology Chief Fellow |
| 2014 | Hematology/Oncology Academic Achievement awarded to the fellow with the highest score on the annual ASCO in-service exam, UT Southwestern |
| 2011 | Parkland Hospital Employee of the Month |
| 2005 - 2006 | Southwestern Medical Foundation Scholarship for Academic Achievement |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Sahai V, Rothe M, Mangat PK, Garrett-Mayer E, Suhag V, Dib EG, Mehmi I, Kadakia KC, Pisick E, Duvivier HL, Le P, Li R, Michelin DP, Wilcox RE, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Regorafenib in Patients with Solid Tumors with BRAF Alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol 8:e2300527, 2024. e-Pub 2024. PMID: 38603652.
- Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
- Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y. Predictors and Impact of Second-line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: real-world considerations for maintenance therapy. J Thorac Oncol 6(2):365-71, 2011. e-Pub 2011. PMID: 21173713.
Abstracts
- Shah AT, Estrella J, Dasari P, Willett A, Allam J, Higbie V, Le P, Lee MS, Matamoros A, Lano EA, Raghav KPS, Huey RW. Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset. J Clin Oncol 41(16):3606, 2023. e-Pub 2023.
- Morris VK, Parseghian CM, Escano M, Johnson B, Raghav KPS, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, Le P, Margain C, Gallup D, Tam A, Foo WC, Xiao L, Yun K, Kopetz S. Phase I/II trial of enorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAF V600E metastatic colorectal cancer. J Clin Oncol 40(16):3598, 2022. e-Pub 2022.
- Simmons K, Kee BK, Raghav KPS, Johnson B, Kopetz S, Willis J, Dasari A, Sanchez EV, Ludford K, Parseghian M, Lee MS, Le P, Shen JP, Overman MJ, Morris VK. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. J Clin Oncol 40(16):3585, 2022. e-Pub 2022.
- Johnson B, Yang D, Dada HI, Morris VK, Wang X, Dasari A, Raghav KPS, Kee BK, Shen JP, Huey R, Lee MS, Parseghian CM, Le P, Morelli MP, Willis J, Wolff RA, Drusbosky L, Overman MJ, Kopetz S. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. J Clin Oncol 40(16):3592, 2022. e-Pub 2022.
- Bhamidipati D, Raghav KPS, Morris VK, Kopetz S, Kee BK, Johnson B, Willis J, Dasari A, Morelli MP, Parseghian CM, Lee MS, Le P, Shen JP, Ludford K, Overman M. Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy. J Clin Oncol 40(16):3524, 2022. e-Pub 2022.
- Wiele AJ, Nguyen T, Ononogbu A, Russo KM, Le P, Patel TA, Ma HY, Rieber AG. Reducing the wait time to initiate inpatient chemotherapy at Lyndon B. Johnson Hospital. J Clin Oncol; ASCO Quality Care Symposium, Poster Highlights Session, October 2020 38(29), 2020. e-Pub 2020.
- Wiele AJ, Nguyen T, Ononogbu A, Russo KM, Le P, Patel TA, Ma HY, Rieber AG. Reducing the wait time to initiate inpatient chemotherapy at Lyndon B. Johnson Hospital. J Clini Oncol; ASCO Quality Care Symposium, Poster Highlights Session, October 2020 38(29), 2020. e-Pub 2020.
- Le P, Law JY, Dao BD, Ahn C, Kumar K, Anderson LD, Collins R, Li HC, Patel PA, Sadeghi N, Vusirikala M, Scaglioni PP, Naina HV. Treatment of adolescent young adults with acute lymphoblastic leukemia: 10-year outcome data from single institution. J Clin Oncol 2015;American Society of Clinical Oncology (ASCO), May 2015, Chicago, IL 33(15), 2015. e-Pub 2015.
- Law JY, Dao BD, Le P, Ahn C, Kumar K, Anderson LD, Collins R, Li HC, Patel PA, Sadeghi N, Vusirikala M, Scaglioni PP, Naina HV. Impact of body mass index and ethnicity on asparaginase toxicity in adult acute lymphoblastic leukemia patients. J Clin Oncol 2015; American Society of Clinical Oncology (ASCO), May 2015, Chicago, IL 33(15), 2015. e-Pub 2015.
- Dao BD, Law JY, Le P, Ahn C, Kumar K, Anderson LD, Collins R, Li HC, Patel PA, Sadeghi N, Vusirikala M, Scaglioni PP, Naina HV. Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status. J Clin Oncol 2015; American Society of Clinical Oncology (ASCO), May 2015, Chicago, IL 33(15), 2015. e-Pub 2015.
- Law JY, Dao BD, Le P, Ahn C, Kumar K, Anderson LD, Collins R, Li HC, Patel PA, Sadeghi N, Vusirikala M, Scaglioni PP, Naina HV. Impact of body mass index and ethnicity on asparaginase toxicity in adult acute lymphoblastic leukemia patients. J Clin Oncol 2015; American Society of Clinical Oncology (ASCO), May 2015, Chicago, IL 33(15), 2015. e-Pub 2015.
Book Chapters
- Ramzan Z, Le P, Kapur P, Huerta S. Current Concepts in Pancreatic Cancer. In: Updates on Cancer Treatment, Prof. Leticia Rangel (Ed.). In TECH, 2015.
Selected Presentations & Talks
Local Presentations
- 2022. Evidence-based Second/Third-line Treatment and Beyond. Invited. Bayer Colorectal Education Session. Houston, Texas, US.
Patient Reviews
CV information above last modified April 02, 2025